Haplotype
CYP2C9*65
Overview
CYP2C9*65 is a specific haplotype found on the cytochrome P450 family 2 subfamily C member 9 gene. This haplotype is intricately connected to 17 specific variants. It plays a significant role in how individuals metabolize certain drugs, especially ketoprofen, diclofenac, ibuprofen, zafirlukast, meloxicam, olanzapine, phenprocoumon, phenytoin, indomethacin, valproic acid, piroxicam, celecoxib, naproxen, tolbutamide, flurbiprofen. CYP2C9*65 has a Haplotype Performance of 100%. The combined haplotype performances of two haplotypes and individual posseses on cytochrome P450 family 2 subfamily C member 9 determines the overall gene performance. The gene performance indicates the metabolism rate, classifying individuals as either poor, intermediate, extensive, or ultrarapid metabolizers. This has a direct influence on how they process certain drugs.
Role of the Gene that carries the Haplotype CYP2C9*65
The gene cytochrome P450 family 2 subfamily C member 9, plays a crucial role in the way our body processes fat by breaking it down and managing its levels. This occurs mostly in the liver, an essential organ for maintaining healthy body functions. The gene can lead to a change in the protein structure, potentially causing inefficient breakdown of fat. This may contribute to an increased risk of developing liver-related health issues such as fatty liver disease. While genetics play a part, maintaining a healthy lifestyle can help minimize these risks.
CYP2C9*65
% Haplotype Performance:
100%
This is the standard or typical haplotype performance. The haplotype performance is at a "normal" level.
The haplotype performances of two haplotypes an individual possess on cytochrome P450 family 2 subfamily C member 9 determines their overall gene performance.
100% Haplotype Performance
The haplotype performance of a haplotype, when considering drug metabolization, provides a quantifiable measure of how effectively a person's genetics might influence their ability to metabolize or break down specific drugs. The combined effect of the two haplotypes you possess (i.e., the two sets of variants) will determine your overall gene performance related to drug metabolism.
Set of variants that define CYP2C9*65
Haplotypes are linked to multiple variants, and each variant in the haplotype has a specific allele.
there are 17 Variants linked to CYP2C9*65 in the databse:
CYP2C9*65
Variant
Allele
Summary
rs1057910
A
rs1057910 is a genetic variant on gene CYP2C9.
rs1799853
C
rs1799853 is a genetic variant on gene CYP2C9.
rs2256871
A
rs2256871 is a genetic variant on gene CYP2C9.
rs7900194
G
rs7900194 is a genetic variant on gene CYP2C9.
rs9332130
A
rs9332130 is a genetic variant on gene CYP2C9.
rs9332131
A
rs9332131 is a genetic variant on gene CYP2C9.
rs9332239
C
rs9332239 is a genetic variant on gene CYP2C9.
rs12414460
G
rs12414460 is a genetic variant on gene CYP2C9.
rs28371685
C
rs28371685 is a genetic variant on gene CYP2C9.
rs28371686
C
rs28371686 is a genetic variant on gene CYP2C9.
rs56165452
T
rs56165452 is a genetic variant on gene CYP2C9.
rs67807361
C
rs67807361 is a genetic variant on gene CYP2C9.
rs72558187
T
rs72558187 is a genetic variant on gene CYP2C9.
rs72558189
G
rs72558189 is a genetic variant on gene CYP2C9.
rs72558190
C
rs72558190 is a genetic variant on gene CYP2C9.
rs72558192
A
rs72558192 is a genetic variant on gene CYP2C9.
rs72558193
A
rs72558193 is a genetic variant on gene CYP2C9.
CYP2C9*65
Did you know that haplotypes play a major role in pharmacogenetics?
Certain haplotypes in combination can influence how a person's body metabolizes drugs. This is because these haplotypes can affect the function of enzymes responsible for drug metabolism. A change or variation in the DNA sequence of a gene that codes for a drug-metabolizing enzyme can increase or decrease the activity of that enzyme.
Based on the activity of these enzymes (influenced by haplotypes), individuals can be classified into different metabolizer categories:
- Poor Metabolizers (PMs): These individuals have little or no enzyme activity due to certain genetic variations. As a result, they might not metabolize certain drugs efficiently, leading to a higher risk of side effects because the drug remains in their system for a longer time.
- Intermediate Metabolizers (IMs): These people have reduced enzyme activity. They metabolize drugs slower than normal metabolizers but faster than poor metabolizers.
- Extensive Metabolizers (EMs): This is the "standard" or "expected" rate of metabolization. Drugs are metabolized at a regular rate, leading to expected drug efficacy and side effects.
- Ultrarapid Metabolizers (UMs): These individuals have increased enzyme activity. They break down certain drugs very quickly, which can decrease the effectiveness of the drug because it's cleared from their system too rapidly.
In conclusion, understanding one's haplotype and consequent metabolizer status can be crucial for personalized medicine. It can provide guidance on drug selection and dosing to optimize therapeutic outcomes and minimize adverse reactions.
Dr. Wallerstorfer
Pharmacogenetics
The CYP2C9*65 haplotype is linked to the CYP2C9 gene, a key component in the body's drug-processing system. This gene provides the blueprint for an enzyme pivotal in breaking down a range of medicines. The presence of the CYP2C9*65 haplotype can influence the efficiency of this enzyme. Based on its activity score, individuals with this haplotype might be classified as poor, intermediate, normal, or ultrarapid metabolizers. This classification is vital as it dictates how rapidly one processes certain medications, potentially impacting the drug's efficacy and risk of side effects. Recognizing the presence of CYP2C9*65 in an individual can guide healthcare professionals in tailoring medication doses to achieve optimal therapeutic outcomes.
there are 20 Drugs associated with 20 Variants that are located on CYP2C9